[go: up one dir, main page]

PT1424997E - Amino acid modulated extended release dosage form - Google Patents

Amino acid modulated extended release dosage form Download PDF

Info

Publication number
PT1424997E
PT1424997E PT02706380T PT02706380T PT1424997E PT 1424997 E PT1424997 E PT 1424997E PT 02706380 T PT02706380 T PT 02706380T PT 02706380 T PT02706380 T PT 02706380T PT 1424997 E PT1424997 E PT 1424997E
Authority
PT
Portugal
Prior art keywords
amino acid
dosage form
extended release
release dosage
modulated extended
Prior art date
Application number
PT02706380T
Other languages
Portuguese (pt)
Inventor
Reza A Fassihi
Thomas Durig
Original Assignee
Scolr Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/042156 external-priority patent/WO2003024427A1/en
Application filed by Scolr Inc filed Critical Scolr Inc
Publication of PT1424997E publication Critical patent/PT1424997E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02706380T 2001-09-14 2002-02-20 Amino acid modulated extended release dosage form PT1424997E (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/042156 WO2003024427A1 (en) 1999-12-20 2001-09-14 Tableted oral extended release dosage form
US09/997,377 US6517868B2 (en) 1999-12-20 2001-11-30 Amino acid modulated extended release dosage form

Publications (1)

Publication Number Publication Date
PT1424997E true PT1424997E (en) 2008-02-28

Family

ID=39777880

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02706380T PT1424997E (en) 2001-09-14 2002-02-20 Amino acid modulated extended release dosage form

Country Status (4)

Country Link
JP (1) JP2012046549A (en)
CY (1) CY1107201T1 (en)
DE (1) DE60223695T2 (en)
PT (1) PT1424997E (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK130287D0 (en) * 1987-03-13 1987-03-13 Benzon As Alfred ORAL PREPARATION
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
TW235239B (en) * 1992-11-20 1994-12-01 Pfizer
DE19747261A1 (en) * 1997-10-25 1999-04-29 Bayer Ag Single-chamber osmotic pharmaceutical release system
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
TR200100931T2 (en) * 1998-10-01 2001-10-22 Novartis Ag New sustained release oral formulations

Also Published As

Publication number Publication date
DE60223695D1 (en) 2008-01-03
DE60223695T2 (en) 2008-10-30
CY1107201T1 (en) 2012-05-23
JP2012046549A (en) 2012-03-08

Similar Documents

Publication Publication Date Title
PL364223A1 (en) Pharmaceutical salts
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
GB0319041D0 (en) Pharmaceutical Formulations
GB0025208D0 (en) Delayed release pharmaceutical formulations
EP1450824A4 (en) Pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
GB0101227D0 (en) Pharmaceutical compounds
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
EP1408896A4 (en) Pharmaceutical composition
GB0101225D0 (en) Pharmaceutical compounds
GB0120701D0 (en) Pharmaceutical formulations
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
GB0103638D0 (en) Pharmaceutical formulations
GB0129988D0 (en) Imidazolidineacetic acid derivatives
GB0105560D0 (en) Pharmaceutical formulations
GB0116107D0 (en) Pharmaceutical composition
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
HUP0401599A3 (en) Extended release oral dosage form
PL366980A1 (en) Hydroxyeicosenoic acid analogs
EP1357898A4 (en) Improved controlled release oral dosage form
EP1424997A4 (en) Amino acid modulated extended release dosage form
PT1424997E (en) Amino acid modulated extended release dosage form
GB0124455D0 (en) Pharmaceutical formulations
ZA200306383B (en) Pharmaceutical formulation comprising bicalutamide.